{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:30:36Z","timestamp":1787056236869,"version":"build-2736575974"},"reference-count":29,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC) Young Scientists Fund","doi-asserted-by":"publisher","award":["82003087"],"award-info":[{"award-number":["82003087"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82003087"],"award-info":[{"award-number":["82003087"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>To investigate the role and underlying mechanisms of TIMM8A in breast cancer progression. The expression of TIMM8A in breast cancer tissues and cell lines was assessed. Functional assays were performed to evaluate the effects of TIMM8A knockdown on proliferation, metastasis, and apoptosis in BT549 and MCF-7 cells. Co-immunoprecipitation (Co-IP) and ubiquitination assays were used to examine the interaction between TIMM8A and HSPA9, as well as the involvement of the E3 ubiquitin ligase RNF4. PI3K\/AKT pathway activity was assessed by Western blotting. In vivo tumor growth was evaluated using a xenograft mouse model. TIMM8A was significantly upregulated in breast cancer tissues and cell lines, and high TIMM8A expression correlated with poor prognosis. TIMM8A knockdown suppressed proliferation and metastasis while inducing apoptosis in vitro. Mechanistically, TIMM8A interacted with HSPA9 and maintained its protein stability by inhibiting RNF4-mediated ubiquitination and degradation, thereby sustaining PI3K\/AKT signaling activation. Conversely, TIMM8A depletion reduced HSPA9 stability and attenuated the pathway. Rescue experiments confirmed that HSPA9 overexpression restored PI3K\/AKT activation and reversed TIMM8A-knockdown-induced malignant suppression. In vivo, TIMM8A silencing efficiently inhibited tumor growth, accompanied by reduced HSPA9 and Ki-67 expression and decreased PI3K\/AKT phosphorylation. TIMM8A promotes breast cancer progression through the TIMM8A\/HSPA9\/PI3K\/AKT regulatory axis, highlighting TIMM8A as a promising prognostic biomarker and potential therapeutic target for breast cancer.<\/jats:p>","DOI":"10.3390\/ijms27167382","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:09:32Z","timestamp":1787054972000},"page":"7382","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Loss of TIMM8A Inhibits Breast Cancer Progression Through Promoting HSPA9 Ubiquitination and Degradation via Competitive Interaction with RNF4"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0414-993X","authenticated-orcid":false,"given":"Yi","family":"Wu","sequence":"first","affiliation":[{"name":"Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6803-0594","authenticated-orcid":false,"given":"Rujiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Phase I Unit, Fudan University Shanghai Cancer Center, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Phase I Unit, Fudan University Shanghai Cancer Center, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiping","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Phase I Unit, Fudan University Shanghai Cancer Center, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Hurvitz","year":"2024","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: Long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): A randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.annonc.2025.12.017","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival analysis of the phase III TROPION-Breast01 study","volume":"37","author":"Pistilli","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1038\/s41598-025-12883-x","article-title":"Patterns and prognostic implications of distant metastasis in breast Cancer based on SEER population data","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"16080","DOI":"10.1038\/nrdp.2016.80","article-title":"Mitochondrial Diseases","volume":"2","author":"Gorman","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1158\/0008-5472.CAN-14-1692","article-title":"Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Breast Cancer","volume":"75","author":"Lemnrau","year":"2015","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/carcin\/bgv130","article-title":"Peripheral blood mitochondrial DNA copy number, length heteroplasmy and breast cancer risk: A replication study","volume":"36","author":"Shen","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_12","first-page":"100931","article-title":"Analysis of mitochondrial DNA copy number variation in blood and tissue samples of metastatic breast cancer patients (A pilot study)","volume":"26","author":"Rai","year":"2021","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"108194","DOI":"10.1016\/j.phrs.2026.108194","article-title":"Metabolic control of immunity and inflammation: Mitochondrial dynamics, pharmacological targets, and therapeutic opportunities","volume":"227","author":"Wang","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/s43018-023-00563-6","article-title":"Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases","volume":"4","author":"Parida","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41419-025-07878-5","article-title":"Metastatic Breast Cancer Cells Are Selectively Dependent on the Mitochondrial Cristae\u2013Shaping Protein OPA1","volume":"16","author":"Diokmetzidou","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/brain\/awg174","article-title":"Clinical and molecular findings in a patient with a novel mutation in the deafness-dystonia peptide (DDP1) gene","volume":"126","author":"Binder","year":"2003","journal-title":"Brain"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1121","DOI":"10.1002\/mgg3.1121","article-title":"Functional analysis of a novel mutation in the TIMM8A gene that causes deafness-dystonia-optic neuronopathy syndrome","volume":"8","author":"Neighbors","year":"2020","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12957-022-02736-6","article-title":"TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy","volume":"20","author":"Zhu","year":"2022","journal-title":"World J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"18374","DOI":"10.1038\/s41598-025-03331-x","article-title":"The oncogenic role of TIMM8A in cancer and the mechanistic insights into the function in breast cancer cells","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41418-020-00708-5","article-title":"Ubiquitination in the regulation of inflammatory cell death and cancer","volume":"28","author":"Cockram","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molmed.2023.05.006","article-title":"The Ubiquitin\u2013Proteasome System in Breast Cancer","volume":"29","author":"Han","year":"2023","journal-title":"Trends Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1158\/0008-5472.CAN-15-2704","article-title":"Stress Chaperone Mortalin Contributes to Epithelial\u2013Mesenchymal Transition and Cancer Metastasis","volume":"76","author":"Na","year":"2016","journal-title":"Cancer Res."},{"key":"ref_23","first-page":"1185","article-title":"Disease burden and economic burden of breast cancer in females in China: A synthesis analysis","volume":"45","author":"Zhou","year":"2024","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70420","DOI":"10.1002\/cncr.70420","article-title":"Antibody\u2013Drug Conjugates in Breast Cancer","volume":"132","author":"Sakach","year":"2026","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.cub.2005.10.041","article-title":"Bax\/Bak-Dependent Release of DDP\/TIMM8a Promotes Drp1-Mediated Mitochondrial Fission and Mitoptosis during Programmed Cell Death","volume":"15","author":"Arnoult","year":"2005","journal-title":"Curr. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chi, Y., Hirachan, S., Zhou, Y., and Bhandari, A. (2024). Exploring the Oncogenic Potential of TIMM8A: A Crucial Factor in Breast Cancer Tumorigenesis. Clin. Breast Cancer, 24.","DOI":"10.1016\/j.clbc.2024.02.011"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12935-022-02530-0","article-title":"ncRNAs-mediated high expression of TIMM8A correlates with poor prognosis and act as an oncogene in breast cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.32604\/or.2025.063812","article-title":"TIMM8A-TIMM13 Complex Exerts Oncogenic Functions in Lung Cancer","volume":"33","author":"Li","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Lin, L., Wu, Y., Bing, P., Zhou, J., and Yu, W. (2022). Upregulation of TIMM8A is correlated with prognosis and immune regulation in BC. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.922178"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7382\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:10:08Z","timestamp":1787055008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":29,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27167382"],"URL":"https:\/\/doi.org\/10.3390\/ijms27167382","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}